Antifungal therapy

Producción científica: Chapter


This chapter focuses on the use of drugs that treat systemic mycoses (Table 204.1). Treatment of cutaneous fungal infections is discussed in Chapter 25, Superficial Fungal Infection of the Hair, Skin, and Nails. AMPHOTERICIN B Amphotericin B is a polyene antifungal synthesized by Streptomyces nodosus. Its chemical structure confers it with amphoteric properties that are essential for the drug’s ability to form channels through the cytoplasmatic membrane. The pores formed from preferential binding of amphotericin B to ergosterol, the primary fungal cell sterol, result in an increase in membrane permeability, leading to a loss of essential elements such as potassium and other molecules that impairs fungal viability. Amphotericin B binds with less affinity to cholesterol, the primary cell sterol of mammalian cells, which are therefore less affected by amphotericin B than is the fungal target. Amphotericin B is commercially available as a complex with sodium deoxycholate: commercial vials contain amphotericin B, 50 mg, sodium deoxycholate, 41 mg, and a sodium phosphate buffer, 25.2 mg. The clinical pharmacology of amphotericin B is characterized by extensive binding to plasma proteins (>90%) and wide distribution to the peripheral compartment with preferential accumulation in liver and spleen, with lesser amounts in kidney and lung. Intravenous administration of therapeutic doses results in peak plasma levels of 1.0 to 1.5 μg/mL falling to 0.5 to 1.0 μg/mL 24 hours later. At therapeutic doses, less than 5% of the drug each dose is excreted in the urine.

Idioma originalEnglish (US)
Título de la publicación alojadaClinical Infectious Disease
EditorialCambridge University Press
Número de páginas10
ISBN (versión digital)9780511722240
ISBN (versión impresa)9780521871129
EstadoPublished - ene 1 2010

ASJC Scopus subject areas

  • General Medicine


Profundice en los temas de investigación de 'Antifungal therapy'. En conjunto forman una huella única.

Citar esto